NCT02336139View on ClinicalTrials.gov

A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

March 16, 2016

Primary Completion Date

April 17, 2017

Study Completion Date

November 28, 2018

Conditions
Hepatitis C
Interventions
DRUG

Sofosbuvir (SOF)/GS-5816

12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose

Trial Locations (1)

2052

The Kirby Institute, Sydney

Sponsors

Lead Sponsor

Kirby Institute
All Listed Sponsors
lead

Kirby Institute

OTHER_GOV